Mylan CEO to be Grilled by Congress Over EpiPen Pricing
Mylan NV’s chief executive officer will make a very different trip to Washington next week, years after she helped successfully lobby for expanded use of the company’s EpiPen allergy shot.
CEO Heather Bresch is scheduled to appear before the U.S. House Committee on Oversight and Government Reform on Sept. 21, when members will question her about how the company raised the price of the life-saving injection to $600 for a two-pack, from $57 a shot when it took over sales of the product in 2007.
“There is justified outrage from families and schools across the country struggling to afford the high cost of EpiPens,” committee Chairman Jason Chaffetz, a Republican from Utah, said in a joint statement announcing the hearing with Democratic Representative Elijah Cummings of Maryland.
CEO Heather Bresch is scheduled to appear before the U.S. House Committee on Oversight and Government Reform on Sept. 21, when members will question her about how the company raised the price of the life-saving injection to $600 for a two-pack, from $57 a shot when it took over sales of the product in 2007.
“There is justified outrage from families and schools across the country struggling to afford the high cost of EpiPens,” committee Chairman Jason Chaffetz, a Republican from Utah, said in a joint statement announcing the hearing with Democratic Representative Elijah Cummings of Maryland.